On December 11, 2023, following positive results from two published Phase 3 studies, MAPS Public Benefit Corporation (MAPS PBC) submitted a New Drug Application (NDA) to the Federal Drug Administration (FDA) for an investigational MDMA-assisted therapy for persons suffering from post-traumatic ...